The FDA has approved Teoxane and Revance's RHA Dynamic Volume for cheek augmentation, and also for the correction of age-related midface contour deficiencies in adults aged 22 years or older. The filler, formerly known as RHA 4 Mepi from the Teoxane RHA Collection, will formally launch under its new name in early 2026.
The approval follows a 52-week Phase III clinical trial examining patients with moderate to severe midface volume deficiency. During the trial, 75% of subjects and their superficial and deep fat layers were treated. Patients reported improved satisfaction with cheek attractiveness, youthfulness, smoothness, contour and symmetry, according to a Jan. 13 press release.
“The new midface indication enables us to meet more patient needs than ever before," said Nadeem Moiz, CEO of Revance.
Over 94% of participants said their results looked and felt natural, whether at rest or in motion, up to a year after treatment. Patients reported no restrictions in facial movement, underscoring the filler’s ability to move naturally with expressions.
“This study marks the U.S. introduction of a midface contouring approach that has been supported by more than a decade of post-marketing surveillance in Europe," stated Sandra Chennoufi, Chief Scientific Officer of Teoxane. "Leveraging the versatility of RHA Dynamic Volume and the Teoxane MLT Multilayering Technique, physicians can now address midface volume deficiencies by targeting multiple tissue depths for deep and superficial fat pads."
